海外の治験の状況「前立腺癌」での検索結果
241件の検索結果
- 進捗状況
- 試験名
- 対象疾患名
- 国名
- 登録日
Authorised
- A randomized, double-blind phase II trial to assess the efficacy and safety of bicalutamide (Casodex® ) associated to ZD6474 (Zactima™ ) or to placebo in patients with castration-refractory metastatic prostate cancer without any clinical symptom related to disease progression.
- Metastatic prostate cancer br>MedDRA version: 9.1 Level: LLT Classification code 10036909 Term: Prostate cancer metastatic
- France
- 2007-05-10
Authorised
- Neoadjuvant docetaxel prior to radical prostatectomy for high risk localised prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacy. - CANCAP01
- Neoadjuvant docetaxel prior to radical prostatectomy for high risk localised prostate cancer. Evaluation of biological and functional imaging surrogates of therapy efficacy
- United Kingdom
- 2009-10-23
Authorised
- Phase III prospective clinical trial: 18F-FCH/PET evaluation in early diagnosis of disease recurrence in prostate cancer - FCH_PET
- Clinical suspicion of disease relapse in prostate cancer br>MedDRA version: 9.1 Level: HLT Classification code 10036966 Term: Prostatic neoplasms and hypertrophy
- Italy
- 2009-03-13
Authorised
- A Randomized, Open Label, Phase III, Multicenter, 2-Arm Study of Androgen deprivation +/- Taxotere? (Docetaxel) for Non metastatic Prostate Cancer Patients with a Rising PSA. - PSA-ERECT
- Patients with prostate cancer. The study will include two patient cohorts, which at inclusion has a similar risk for progression of the disease at 5 years, and risk of later prostate cancer death. The first patient group are patients with PSA relapse after curative treatment, and the 2nd one are patients with locally advanced disease. MedDRA version: 9.1 Level: LLT Classification code 10036910 Term: Prostate cancer NOS
- Denmark, Finland, Netherlands, Sweden
- 2008-09-17
Authorised
- DNA Vaccine Coding for the Rhesus Prostate Specific Antigen (rhPSA) and Electroporation in Patients with Relapsed Prostate Cancer. A Phase I/II Study
- Patients with relapse of prostate cancer.
- Sweden
- 2008-06-23
Authorised
- A randomised study to compare combination therapy of Rhenium with Docetaxel versus Docetaxel alone in patients with prostate cancer no longer sensitive to hormonal treatment and bone metastases
- Men with castration resistant prostate cancer (CRPC) metastatic to bone MedDRA version: 16.1 Level: LLT Classification code 10036921 Term: Prostate carcinoma System Organ Class: 100000004864 MedDRA version: 16.1 Level: LLT Classification code 10005993 Term: Bone metastases System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04]
- Netherlands
- 2011-08-31
Authorised
- A phase II single arm, multi-centre trial of triamcinolone with a GnRH analog for castration resistant prostate cancer
- Castration Resistent Prostate cancer;Therapeutic area: Diseases [C] - Male diseases of the urinary and reproductive systems [C12]
- United Kingdom
- 2011-05-09
Authorised
- A MULTINATIONAL, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE III EFFICACY AND SAFETY STUDY OF DAROLUTAMIDE (DCM-201) IN MEN WITH HIGH-RISK NON-METASTATIC CASTRATION-RESISTANT PROSTATE CANCER
- High-risk, non-metastatic castration-resistant prostate cancer (MedDRA: hormonerefractory prostate cancer) br>MedDRA version: 20.0 Level: LLT Classification code 10066489 Term: Progression of prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) MedDRA version: 20.0 Level: PT Classification code 10062904 Term: Hormone-refractory prostate cancer System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) ;Therapeutic area: Diseases [C] - Cancer [C04]
- Argentina, Australia, Austria, Belarus, Belgium, Brazil, Bulgaria, Canada, Colombia, Czech Republic, Estonia, Finland, France, Germany, Hungary, Israel, Italy, Japan, Korea, Republic of, Latvia, Lithuania, Peru, Poland, Portugal, Romania, Russian Federation, Serbia, Slovakia, South Africa, Spain, Sweden, Taiwan, Turkey, Ukraine, United Kingdom, United States
- 2014-06-05
Authorised
- A prospective randomised phase III study of androgen deprivation therapy with or without local radiotherapy with or without abiraterone acetate and prednisone in patient with metastatic hormone-naïve prostate cancer.
- metastatic hormone-naïve prostate cancer br>MedDRA version: 16.0 Level: PT Classification code 10036909 Term: Prostate cancer metastatic System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)
- Belgium, Denmark, Finland, France, Germany, Greece, Ireland, Italy, Netherlands, Poland, Spain, Sweden, Switzerland, United Kingdom
- 2013-05-22
Authorised
- A Phase I/II Open Label Study of the 17a-hydroxylase/ C17,20 lyase inhibitor, Abiraterone acetate, in Patients with Prostate Cancer who have failed hormone therapy
- Hormone refractory prostate cancer MedDRA version: 8.0 Classification code 10062904
- United Kingdom
- 2005-08-31